Retinoid X receptor ligands: A patent review (2007-2013)

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 4, 2014, Pages 443-452

  Yamada, Shoya ^a,b   Kakuta, Hiroki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

Alzheimer's disease; Atherosclerosis; Cancer; Diabetes; Permissive mechanism; Retinoid X receptor heterodimers; Retinoid X receptors; Revival drug discovery; Rexinoids; Western style Chinese medicine

Indexed keywords

3 METHYL 7 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 3 PROPOXY 2 NAPHTHYL) 2,4,6 OCTATRIENOIC ACID; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; 9CRA; AGN 194204; BEXAROTENE; GLITAZONE DERIVATIVE; KAMPO; LG 100364; LG 101305; LG 101506; LIGAND; MX 6054; NET 3IP; PHYTANIC ACID; RETINOID; RETINOID X RECEPTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT;

ALLERGY; ALZHEIMER DISEASE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CHINESE MEDICINE; CUTANEOUS T CELL LYMPHOMA; DRUG TARGETING; DYSLIPIDEMIA; HEPATOMEGALY; HUMAN; HYPOTHYROIDISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATENT; REVIEW; SIDE EFFECT; TERATOGENICITY; TRIACYLGLYCEROL BLOOD LEVEL; AGONISTS; ANIMAL; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DRUG DEVELOPMENT; PROTEIN MULTIMERIZATION;

ALZHEIMER DISEASE; ANIMALS; ANTINEOPLASTIC AGENTS; DIABETES MELLITUS, TYPE 2; DRUG DISCOVERY; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; LIGANDS; MEDICINE, CHINESE TRADITIONAL; PATENTS AS TOPIC; PROTEIN MULTIMERIZATION; RETINOID X RECEPTORS;

EID: 84896462023     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.880692     Document Type: Review

References (111)

1. Leid M, Kastner P, Chambon P. Multiplicity generates diversity in the retinoic acid signaling pathways. Trends Biochem Sci 1992;17:427-33
2. Glass CK, Rosenfeld CK. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000;14:121-41
3. Moraes LA, Swales KE, Wray JA, et al. Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood 2007;109:3741-4
4. Germain P, Chambon P, Eichele G, et al. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 2006;58:760-72
5. Allenby G, Bocquel MT, Saunders M, et al. Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci USA 1993;90:30-4
6. Egea PF, Mitschler A, Moras D. Molecular Recognition of Agonist Ligands by RXRs. Mol Endocrinol 2002;16:987-97
7. Kitareewan S, Burka LT, Tomer KB, et al. Phytol metabolites are circulating dietary factors that activate the nuclear receptor RXR. Mol Biol Cell 1996;7:1153-66
8. Lemotte PK, Keidel S, Apfel CM. Phytanic acid is a retinoid X receptor ligand. Eur J Biochem 1996;236:328-33
9. Harmon MA, Boehm MF, Heyman RA, et al. Activation of mammalian retinoid X receptors by the insect growth regulator methoprene. Proc Natl Acad Sci USA 1995;92:6157-60
10. Kotani H, Tanabe H, Mizukami H, et al. Identification of a naturally occurring rexinoid, honokiol, that activates the retinoid X receptor. J Nat Prod 2010;73:1332-6
11. Zhang H, Zhou R, Li L, et al. Danthron functions as a retinoic X receptor antagonist by stabilizing tetramers of the receptor. J Biol Chem 2011;286:1868-75
12. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9
13. Shulman AI, Larson C, Mangelsdorf DJ, et al. Structural determinants of allosteric ligand activation in RXR heterodimers. Cell 2004;116:417-29
14. Bettoun DJ, Burris TP, Houck KA, et al. Retinoid X receptor is a nonsilent major contributor to vitamin D receptor-mediated transcriptional activation. Mol Endocrinol 2003;17:2320-8
15. Putcha BD, Wright E, Brunzelle JS, et al. Structural basis for negative cooperativity within agonist-bound TR: RXR heterodimers. Proc Natl Acad Sci USA 2012;109:6084-7
16. Moore DD, Kato S, Xie W, et al. International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol Rev 2006;58:742-59
17. Chawla A, Boisvert WA, Lee CH, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001;7:161-71
18. Szanto A, Benko S, Szatmari I, et al. Transcriptional regulation of human CYP27 integrates retinoid, peroxisome proliferator-activated receptor, and liver X receptor signaling in macrophages. Mol Cell Biol 2004;24:8154-66
19. Lagu B, Lebedev R, Pio B, et al. Dihydro-[1H]-quinolin-2-ones as retinoid X receptor (RXR) agonists for potential treatment of dyslipidemia. Bioorg Med Chem Lett 2007;17:3491-6
20. Lagu B, Pio B, Lebedev R, et al. RXR-LXR heterodimer modulators for the potential treatment of dyslipidemia. Bioorg Med Chem Lett 2007;17:3497-503
21. Claudel T, Leibowitz MD, Fievet C, et al. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci USA 2001;98:2610-15
22. Lalloyer F, Fievet C, Lestavel S, et al. The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 2006;26:2731-7
23. Dawson MI, Xia Z. The retinoid X receptors and their ligands. Biochim Biophys Acta 2012;1821:21-56
24. Gaster M, Staehr P, Beck-Nielsen H, et al. GLUT4 is reduced in slow muscle fibers of type 2 diabetic patients: is insulin resistance in type 2 diabetes a slow, type 1 fiber disease? Diabetes 2001;50:1324-9
25. Galgani JE, Uauy RD, Aguirre CA, et al. Effect of the dietary fat quality on insulin sensitivity. Br J Nutr 2008;100:471-9
26. Siersbaek R, Nielsen R, Mandrup S. PPARgamma in adipocyte differentiation and metabolism-novel insights from genome-wide studies. FEBS Lett 2010;584:3242-9
27. Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33
28. Chou FS, Wang PS, Kulp S, et al. Effects of thiazolidinediones on differentiation, proliferation, and apoptosis. Mol Cancer Res 2007;5:523-30
29. Hammarstedt A, Andersson CX, Rotter Sopasakis V, et al. The effect of PPARgamma ligands on the adipose tissue in insulin resistance. Prostaglandins Leukot Essent Fatty Acids 2005;73:65-75
30. Forman BM. The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands. J Biol Chem 2002;277:12503-6
31. Michellys PY, Ardecky RJ, Chen JH, et al. Novel (2E, 4E, 6Z)-7-(2-alkoxy-3, 5-dialkylbenzene)-3-methylocta-2, 4, 6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes. J Med Chem 2003;46:2683-96
32. Michellys PY, Ardecky RJ, Chen JH, et al. Design, synthesis and structure-activity relationship studies of novel 6, 7-locked-[7-(2-alkoxy-3, 5-dialkylbenzene)-3-methylocta]-2, 4, 6-trienoic acids. J Med Chem 2003;46:4087-103
33. Hamilton Brook, Smith & Reynolds, P.C. Retinoid X receptor moderators. US0090860A1; 2008
34. Kim SY, Kim HI, Kim TH, et al. SREBP-1c mediates the insulin-dependent hepatic glucokinase expression. J Biol Chem 2004;279:30823-9
35. Laffitte BA, Chao LC, Li J, et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA 2003;100:5419-24
36. Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 2006;103:1006-11
37. Singh Ahuja H, Liu S, Crombie DL, et al. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Mol Pharmacol 2001;59:765-73
38. Altucci L, Leibowitz MD, Ogilvie KM, et al. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007;6:793-810
39. Li X, Hansen PA, Xi L, et al. Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor gamma and retinoic acid X receptors. J Biol Chem 2005;280:38317-27
40. Vu-Dac N, Gervois P, Torra IP, et al. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids. J Clin Invest 1998;102:625-32
41. Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999;340:1075-9
42. Liu S, Ogilvie KM, Klausing K, et al. Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat. Endocrinology 2002;143:2880-5
43. Ortho-McNeil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators. US075864A1; 2009
44. Kakuta H, Yakushiji N, Shinozaki R, et al. RXR partial agonist CBt-PMN exerts therapeutic effects on type 2 diabetes without the side effects of RXR full agonists. ACS Med Chem Lett 2012;3:427-32
45. Ohsawa F, Yamada S, Yakushiji N, et al. Mechanism of retinoid X receptor partial agonistic action of 1-(3, 5, 5, 8, 8-pentamethyl-5, 6, 7, 8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carbox ylic acid and structural development to increase potency. J Med Chem 2013;56:1865-77
46. University Okayama. Nuclear receptor ligand. JP111588A; 2010
47. University Okayama. RXR partial agonist. JP177329A; 2013
48. Yamauchi T, Waki H, Kamon J, et al. Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 2001;108:1001-13
49. Sakaki J, Kishida M, Konishi K, et al. Synthesis and structure-activity relationship of novel RXR antagonists: orally active anti-diabetic and anti-obesity agents. Bioorg Med Chem Lett 2007;17:4804-7
50. Yotsumoto T, Naitoh T, Kanaki T, et al. A retinoid X receptor antagonist, HX531, improves leptin resistance without increasing plasma leptin level in KK-Ay mice under normal dietary conditions. Metabolism 2005;54:573-8
51. Nakatsuka A, Wada J, Hida K, et al. RXR antagonism induces G0/G1 cell cycle arrest and ameliorates obesity by up-regulating the p53-p21(Cip1) pathway in adipocytes. J Pathol 2012;226:784-95
52. Boehm MF, Zhang L, Zhi L, et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 1995;38:3146-55
53. Scientifique Centre National de la Recherche RXR-PPARgamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer. WO070379A1; 2010
54. Fish & Richardson PC. Method and pharmaceutical compositions for treatment of anti-estrogen resistant breast cancer using RXR modulators. US093546A1; 2009
55. Matsushima-Nishiwaki R, Okuno M, Takano Y, et al. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 2003;24:1353-9
56. Shimizu M, Takai K, Moriwaki H. Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci 2009;100:369-74
57. Matsushima-Nishiwaki R, Okuno M, Adachi S, et al. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res 2001;61:7675-82
58. Yoshimura K, Muto Y, Shimizu M, et al. Phosphorylated retinoid X receptor alpha loses its heterodimeric activity with retinoic acid receptor beta. Cancer Sci 2007;98:1868-74
59. Honda M, Yamashita T, Yamashita T, et al. Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer 2013;13:191
60. Wyeth. Use of RXR agonists for the treatment of osteoarthritis. WO102789A2; 2009
61. Io Therapeutics, Inc. Autoimmune disorder treatment using RXR agonists. WO090616; 2013
62. Takamatsu K, Takano A, Yakushiji N, et al. The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4-isopropylphenylamino moiety, NEt-3IP (RXRalpha/beta-dual agonist). ChemMedChem 2008;3:780-7
63. University Okayama. Rexinoid compound having alkoxy group. WO105386A1; 2008
64. University Okayama. Anti-allergic agent comprising RXR agonist as active ingredient. WO041449; 2010
65. Blanchard BJ, Hiniker AE, Lu CC, et al. Elimination of amyloid beta neurotoxicity. J Alzheimers Dis 2000;2:137-49
66. Postina R. Activation of alpha-secretase cleavage. J Neurochem 2012;120(Suppl 1):46-54
67. Verghese PB, Castellano JM, Garai K, et al. ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc Natl Acad Sci USA 2013;110:E1807-16
68. Fukumoto H, Deng A, Irizarry MC, et al. Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels. J Biol Chem 2002;277:48508-13
69. Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012;335:1503-6
70. University Case Western Reserve. RXR agonists compounds and methods. WO056232A2; 2013
71. Fitz NF, Cronican AA, Lefterov I, et al. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013;340:924-c
72. Price AR, Xu G, Siemienski ZB, et al. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013;340:924-d
73. Tesseur I, Lo AC, Roberfroid A, et al. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013;340:924-e
74. Veeraraghavalu K, Zhang C, Miller S, et al. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013;340:924-f
75. Landreth GE, Cramer PE, Lakner MM, et al. Response to comments on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013;340:924-g
76. LaClair KD, Manaye KF, Lee DL, et al. Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol Neurodegener 2013;8:18
77. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 2002;56:365-79
78. Johnson GH, Fritsche K. Effect of dietary linoleic acid on markers of inflammation in healthy persons: a systematic review of randomized controlled trials. J Acad Nutr Diet 2012;112:1029-41; 41 e1-15
79. Black PN. The prevalence of allergic disease and linoleic acid in the diet. J Allergy Clin Immunol 1999;103:351-2
80. Zock PL, Katan MB. Linoleic acid intake and cancer risk: a review and meta-analysis. Am J Clin Nutr 1998;68:142-53
81. Bradley RL, Fisher FF, Maratos-Flier E. Dietary fatty acids differentially regulate production of TNF-alpha and IL-10 by murine 3T3-L1 adipocytes. Obesity (Silver Spring) 2008;16:938-44
82. Nguyen MT, Satoh H, Favelyukis S, et al. JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 2005;280:35361-71
83. Degawa-Yamauchi M, Moss KA, Bovenkerk JE, et al. Regulation of adiponectin expression in human adipocytes: effects of adiposity, glucocorticoids, and tumor necrosis factor alpha. Obes Res 2005;13:662-9
84. Simons PJ, van den Pangaart PS, Aerts JM, et al. Pro-inflammatory delipidizing cytokines reduce adiponectin secretion from human adipocytes without affecting adiponectin oligomerization. J Endocrinol 2007;192:289-99
85. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-95
86. Kovalchuk I, Kovalchuk O, Kalck V, et al. Pathogen-induced systemic plant signal triggers DNA rearrangements. Nature 2003;423:760-2
87. Yadav A, Kataria MA, Saini V, et al. Role of leptin and adiponectin in insulin resistance. Clin Chim Acta 2013;417:80-4
88. Chait A, Bornfeldt KE. Diabetes and atherosclerosis: is there a role for hyperglycemia? J Lipid Res 2009;50 Suppl:S335-9
89. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-85
90. Akter K, Lanza EA, Martin SA, et al. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 2011;71:365-76
91. Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer 2009;16:1103-23
92. Ooi GT, Tseng LY, Tran MQ, et al. Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats. Mol Endocrinol 1992;6:2219-28
93. Weinstein D, Simon M, Yehezkel E, et al. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 2009;25:41-9
94. Sun BF, Kobayashi H, Le N, et al. Effects of insulinlike growth factor binding proteins on insulin-like growth factor-I biodistribution in tumor-bearing nude mice. J Nucl Med 2000;41:318-26
95. Murakami J, Okada R, Fujito Y, et al. Paired pulse ratio analysis of insulin-induced synaptic plasticity in the snail brain. J Exp Biol 2013;216:1771-3
96. Shiiki T, Ohtsuki S, Kurihara A, et al. Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci 2004;24:9632-7
97. Banks WA. The source of cerebral insulin. Eur J Pharmacol 2004;490:5-12
98. Moreira RO, Campos SC, Soldera AL. Type 2 diabetes mellitus and Alzheimer's disease: from physiopathology to treatment implications. Diabetes Metab Res Rev 2013; In press, doi: 10.1002/dmrr.2442
99. Hamel FG. In vitro inhibition of insulin-degrading enzyme by long-chain fatty acids and their coenzyme A thioesters. Endocrinology 2003;144:2404-8
100. McAlpine FE, Tansey MG. Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease. J Inflamm Res 2008;1:29-39
101. Yngvadottir B. Insights into modern disease from our distant evolutionary past. Eur J Hum Genet 2007;15:603-6
102. Yu F, Takahashi T, Moriya J, et al. Traditional Chinese Medicine and Kampo: a review from the distant past for the future. J Int Med Res 2006;34:231-9
103. Yamakawa J, Motoo Y, Moriya J, et al. Role of Kampo medicine in integrative cancer therapy. Evid Based Complement Alternat Med 2013;2013:570848
104. Hayashi H, Tohda M, Watanabe H, et al. The effects of Choto-san on the mRNA expression of Alzheimer's disease related factors in the permanent ischemic rat brain. Biol Pharm Bull 2005;28:744-6
105. Okamoto H, Chino A, Hirasaki Y, et al. Orengedoku-to augmentation in cases showing partial response to yokukan-san treatment: a case report and literature review of the evidence for use of these Kampo herbal formulae. Neuropsychiatr Dis Treat 2013;9:151-5
106. Lenhard JM, Croom DK, Weiel JE, et al. HIV Protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol 2000;20:2625-9
107. Jiang H, Penner JD, Beard RL, et al. Diminished teratogenicity of retinoid X receptor-selective synthetic retinoids. Biochem Pharmacol 1995;50:669-76
108. Shi H, Zhu P, Sun Z, et al. Divergent teratogenicity of agonists of retinoid X receptors in embryos of zebrafish (Danio rerio). Ecotoxicology 2012;21:1465-75
109. Ohsawa F, Morishita K, Yamada S, et al. Modification at the lipophilic domain of RXR agonists differentially influences activation of RXR heterodimers. ACS Med Chem Lett 2010;1:521-5
110. Kakuta H, Ohsawa F, Yamada S, et al. Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice. Biol Pharm Bull 2012;35:629-33
111. Germain P, Staels B, Dacquet C, et al. Overview of nomenclature of nuclear receptors. Pharmacol Rev 2006;58:685-704